Clinical trials: Ophthalmic Solutions
Dry Eye
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.
- Trial name
- NCT06360133
- Testing
- VVN001 Ophthalmic Solution, 5%, VVN001 Ophthalmic Solution, Vehicle
- Where
- China
- Volunteers
- 700 people
- Sponsor
- VivaVision Biotech, Inc
Dry Eye Syndromes
A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.
The purpose of this study is to assess the safety and effectiveness of SI-614 solution compared with placebo solution in treating patients with dry eye.
- Trial name
- NCT02205840
- Testing
- SI-614, Vehicle
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Seikagaku Corporation
Allergic Conjunctivitis
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen…
- Trial name
- NCT00769886
- Testing
- Ketotifen/naphazoline, Ketotifen, Naphazoline
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Study of OT202 in Treating Moderate to Severe Dry Eye
This is a phase II study to explore the optimal dosage of OT202 in treating dry eye.
- Trial name
- NCT06435182
- Testing
- OT202 conc 0.5%, OT202 conc 0.1%
- Where
- 10 sites in China
- Volunteers
- 213 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Myopia
Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression
Axial myopia is a type of nearsightedness that happens when the eye is too long from front to back. This causes distant vision to be blurry.
- Trial name
- NCT07522242
- Testing
- T10430 lower dose, T10430 middle dose, T10430 higher dose
- Where
- 10 sites in Jordan, South Africa and 1 more
- Volunteers
- 200 people
- Sponsor
- Laboratoires Thea
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Open-angle Glaucoma, Ocular Hypertension
Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00690794
- Testing
- Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®), Latanoprost ophthalmic solution 0.005% (XALATAN®)
- Volunteers
- 726 people
- Sponsor
- Alcon Research
Neurotrophic Keratitis
A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects
This trial is a Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of STSP-0902 ophthalmic solution in healthy subjects following single and multiple administrations.
- Trial name
- NCT06597422
- Testing
- STSP-0902 ophthalmic solution
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Anti-biotic Resistance
A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms
The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2…
- Trial name
- NCT00874887
- Testing
- moxifloxacin 0.5% HCI ophthalmic solution, gatifloxacin ophthalmic solution 0.3%
- Where
- 2 sites in United States, Canada
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Allergan
Healthy
Study of ESBA105 Eye Drops in Healthy Subjects
Objectives: To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers.
- Trial name
- NCT00671619
- Testing
- ESBA105
- Where
- Switzerland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- ESBATech AG
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Dry Eye Disease (DED)
Cross-linked CMC and Silk Proteins in Eye Disease
Data analyses and revision of the DED symptoms. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market.
- Trial name
- NCT06605365
- Testing
- CX-HA and CS
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- D&V FARMA srl
Open Angle Glaucoma, Ocular Hypertension
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost.
- Trial name
- NCT01789736
- Testing
- PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%
- Where
- 21 sites in United States
- Volunteers
- 234 people
- Sponsor
- Aerie Pharmaceuticals
Healthy Subjects
A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel With Timolol Maleate Gel
The goal of this clinical trial is: 1)To evaluate the pharmacokinetic profiles and safety of 0.5% Timolol Maleate Ophthalmic Gel Forming Solution in healthy adult subjects after multiple dosing; 2)To compare the systemic exposure…
- Trial name
- NCT06813807
- Testing
- 0.5% TM
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Auson Pharmaceuticals Inc.
Keratoconus
Study of TN-001 Topical Eyedrops for Keratoconus
The goal of this clinical trial is to learn if TN-001, a new eye-drop therapy, is safe and well-tolerated in adult patients with progressive keratoconus.
- Trial name
- NCT07388069
- Testing
- Low-dose TGF-B3 and Dexamethasone Sodium Phosphate, High-dose TGF-B3 and Dexamethasone Sodium Phosphate
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- TheiaNova Ltd.
Viral Conjunctivitis
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC.
- Trial name
- NCT01977443
- Testing
- APD-209 Eye drops
- Where
- 10 sites in Germany, Poland and 1 more
- Volunteers
- 47 people
- Sponsor
- Adenovir Pharma AB
Inflammation, Pain
Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
The primary objective of this study is to assess the efficacy and safety of 2 concentrations of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of ocular inflammation and pain in subjects…
- Conditions
- Inflammation, Pain, Cataract
- Trial name
- NCT02329743
- Testing
- RX-10045
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- A.T. Resolve SARL
Glaucoma, Open-Angle
H-1337 Ophthalmic Solution Phase 1/2
The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with…
- Trial name
- NCT03452033
- Testing
- H-1337 [1], H-1337 [2], H-1337 [3]
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Allysta Pharmaceutical
Glaucoma, Open-Angle, Ocular Hypertension
Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension
A study to evaluate the long-term safety of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) in Chinese patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blocker or…
- Trial name
- NCT02571712
- Testing
- bimatoprost 0.03% plus timolol 0.5%
- Where
- 15 sites in China
- Volunteers
- 750 people
- Sponsor
- Allergan
Keratoconjunctivitis, Ocular Surface Disease
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase).
- Trial name
- NCT03769454
- Testing
- PP-001
- Where
- Austria
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Panoptes Pharma GmbH